ROS-Responsive Ratiometric Two-Photon Probes for Detection and Monitoring of Oxidative Stress for Alzheimer’s Disease
Project Name in Chinese
活性氧響應的比例式雙光子探針用於檢測和監測阿爾茨海默病的氧化應激
Brief description of the Project
Alzheimer’s disease (AD) characterized by a progressive neuronal loss and cognitive decline is the most prevalent form of neurodegenerative dementia. Currently, there is still no single confirmative clinically approved test to diagnose AD yet although one of the neuropathological hallmarks of AD, cerebral senile plaques can be visualized by positron emission tomography (PET). The plaques are mainly composed of amyloid-β (Aβ) peptides. It is known that deposition of Aβ appears a decade or more prior to the onset of any clinical symptoms of the disease. To achieve early detection and diagnostics of high-risk and pre-symptomatic subjects for AD, development of reliable diagnostic AD biomarkers and their detection tools/techniques are urgently needed for early intervention and treatment of the disease. The oxidative stress, overproduction of reactive oxygen species (ROS), is one of the prominent causes of neurotoxicity induced by Aβ, which is shown to eventually lead to neuronal cell death and then dementia. ROS is also shown to be an important therapeutic target in AD. Therefore, it is of great interest to develop a smart tool and/ technique that can directly detect and monitor the presence and the amount of Aβ-induced ROS in the high-risk and diseased brains as an alternative and reliable AD biomarker for disease diagnosis and evaluation of drug treatment efficacy. Toward this end, we propose herein the design and development of novel ratiometric two-photon fluorescent probes for sensing and monitoring of endogenous ROS in cell models of AD, living AD brain tissue and an AD mouse model in vivo. With such versatile probes, an investigation of the pathological effect of ROS, an evaluation of the disease progression for early diagnosis of AD and an assessment of drug treatment efficacy would then be achievable.
Academic Discipline of the Research Project
Chemistry
Academic Discipline (specifically) in Chinese
0703 化學
Is this an inter-disciplinary project ?
Yes
Discipline 1)
Detection and Diagnostic Probe of Biomarkers
Academic Discipline (specifically) in Chinese
0703 化學
Discipline 2)
Detection, Diagnostics and Therapeutics for Alzheimer’s Disease
Academic Discipline (specifically) in Chinese
0805 材料科學與工程
Special Requirement for the Postdoctoral Fellow Candidates(if any)
Good Chemistry or Material Sciences Background
Academic Qualifications
9/07−present Professor, Department of Chemistry, Hong Kong Baptist University
9/11−8/2014 Head of Department of Chemistry, Hong Kong Baptist University
9/03−8/2007 Associate Professor, Department of Chemistry, Hong Kong Baptist University
8/98−8/2003 Assistant Professor, Department of Chemistry, Hong Kong Baptist University
Professional Accomplishments, Honors, Awards and Patents
(14) S.-L. Ho, H.-N. Chan, D. Xu, H.W. Li, R.M.S. Wong, “Magnetic Platform for Direct and Multiplex Immune-Based Detection of Trace Amount of Protein Biomarkers” US Patent No.: US 10739336 B2 (2020) (granted on 11 Aug 2020)
(13) 张宏杰, 黄文成, 郭磊, 曾少慧, 刘抗伦, 张彤鑫 “二萜类衍生物作为抗癌剂的用途” 中国,CN 109790140 A (21 May 2019)
(12) H. Zhang, R.M.S. Wong, L. Guo, S.W. Tsang, K. Liu, T. Zhang, “The Use of Diterpenoid Derivatives as Novel Anticancer Agents” US Patent No. US 9795589 B1 (24 Oct 2017)
(11) Y. Li, D. Xu, S.-L. Ho, C.-Y. Poon, H.-N. Chan, H.W. Li, R.M.S. Wong, “Imaging Beta-Amyloid Peptides Aggregation” US Patent No. US 9795694 B2 (24 Oct 2017)
(10) 杨王贵,黄怡,吴芷桦,李红荣,翁建霖,邝维正,黄文成“β淀粉样肽的成像及β淀粉样肽的聚集的抑”2016,中国,CN 102743769 B (2 Nov 2016)
(9) L. Guo, D. Xu, S.-L. Ho, C.-Y. Poon, O. T. W. Ng, H.W. Li, K.K.L. Yung, D.W.J. Kwong, R.M.S. Wong, “Imaging Beta-Amyloid Peptides and Inhibition of Beta-Amyloid Peptide Aggregation”, US Patent No. US 9403794 B2 (2 Aug 2016).
(8) L. Guo, D. Xu, S.-L. Ho, C.-Y. Poon, O. T. W. Ng, H.W. Li, K.K.L. Yung, D.W.J. Kwong, R.M.S. Wong, “Imaging Beta-Amyloid Peptides and Inhibition of Beta-Amyloid Peptide Aggregation”, US Patent No. US 9255933 B2 (9 Feb 2016).
(7) R.M.S. Wong, W. Zhang, L. Guo Low Bandgap Dicyanovinyl and Tricyanovinyl Oligothiophenes for Solar Cell Applications US Patent No. 9147848 B2 (29 Sept 2015).
(6) 黄文成, 张卫锋, 郭磊, "用于太阳能电池应用的低带隙的二氰基乙烯基和三氰基乙烯基低聚噻吩",中国,CN 103524481 B (19 Aug 2015).
(6) W. Yang, Y. Wong, O.T.W. Ng, H.W. Li, K.K.L. Yung, D.W.J. Kwong, R.M.S. Wong, “Imaging Beta-Amyloid Peptides and Inhibition of Beta-Amyloid Peptide Aggregation”, US Patent No. 9156814 B2 (13 Oct 2015).
(4) 夏萍芳, 高志强, 黄文成, 谢国伟, 陈金鑫, “N,N'-双(三苯胺基)芴二胺类空穴注入材料的制备及其用途”, 中国, CN 101671256 B (23 Jan 2013)
(3) 夏萍芳, 高志强, 黄文成, 谢国伟, 陈金鑫, “一种有机电致发光器件”, 中国, CN 201178102 Y (07Jan 2009).
(2) Y. Tao, M. D’Iorio and M.S. Wong, Use of Oligophenylenevinylenes in Organic Light Emitting Devices, United States Patent: US 6733904 B2 (2004)
(1) M.S. Wong, F. Pan, C. Bosshard and P. Günter, Orientierungsoptimierte azentrische Co-Kristalle insbesondere für nichtlinear optische und elektro-optische Bauteile (Orientationally Optimized Acentric Co-crystals Especially for Nonlinear Optical and Electro-optical Components), Swiss Patent: CH-687259A5 (1996).
Are you a member of the Society of Hong Kong Scholars?
No
Research direction and research fund
Major Research Interests
Development of (1) diagnostic tools and treatment drugs for Alzheimer’s disease, (2) novel functional molecules for multiphoton excited amplified stimulated emission, imaging and sensing, as well as (3) advanced materials for organic electronics.
Number of Current PhD Students
3
Number of PhD Trained
12
Number of Postdoctoral Fellows Supervised
10
Active Research Grants in the Capacity of PI
2022-24: Principal and sole investigator, “ROS-Responsive Ratiometric Two Photon Probes for Detection and Monitoring of Oxidative Stress for Alzheimer’s Disease” (GRF, 666,015).
2021-23: Principal and sole investigator, “Oligomeric Amyloid-β Targeted Multimodal Imaging Nanoprobe for Alzheimer’s Disease Mouse Model” (GRF, $666,512).
2020-22: Principal investigator, “From Early Detection, Diagnostics to Therapeutics of Alzheimer’s Disease” (IRCMS, $1,500,000)